share_log

ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul...

ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul...

ATE.TO:奧替那普索的急性疼痛計劃正在進行中。
Benzinga Real-time News ·  2022/09/12 12:05
By David Bautz, PhD
作者:David Bautz博士
OTC:ATBPF | TSX:ATE.TO
場外交易:ATBPF|多倫多證交所:ATE.TO
READ THE FULL ATE.TO RESEARCH REPORT
閲讀完整的ATE研究報告
Business Update
商業動態
Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22
第二階段術後疼痛計劃將於22季度日曆啟動
Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE) is developing otenaproxesul as a solution to the dose-related gastrointestinal (GI) side effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). It uses naproxen as a base molecule with a hydrogen sulfide moiety covalently attached. Hydrogen sulfide (H2S) is an important gasotransmitter, which is a gas that serves as an important signaling molecule in the body.
安替比治療公司(場外交易代碼:ATBPF)(多倫多證券交易所市場代碼:ATE)正在開發一種治療非類固醇抗炎藥(NSAIDs)引起的與劑量相關的胃腸道(GI)副作用的解決方案。它使用萘普生作為鹼基分子,與硫化氫部分共價連接。硫化氫(H)2S)是一種重要的氣體傳遞器,它是一種氣體,在人體內充當重要的信號分子。
The company is developing otenaproxesul for the management of acute...
該公司正在開發用於治...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論